A randomized controlled trial of intralesional bevacizumab injection on primary pterygium: Preliminary results
Purpose: To evaluate the efficacy and safety of intralesional injection of bevacizumab on primary pterygium treatment. Methods: In this randomized controlled trial, each primary pterygium patient was randomized to receive either an intralesional injection of bevacizumab 2 mg (1 mg/0.04 mL) or a comb...
Saved in:
Main Authors: | , , , , |
---|---|
Other Authors: | |
Format: | Article |
Published: |
2018
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/12245 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
id |
th-mahidol.12245 |
---|---|
record_format |
dspace |
spelling |
th-mahidol.122452018-05-03T15:23:37Z A randomized controlled trial of intralesional bevacizumab injection on primary pterygium: Preliminary results Orapin Enkvetchakul Onsiri Thanathanee Ram Rangsin Kaevalin Lekhanont Olan Suwan-Apichon Khon Kaen University Phramongkutklao College of Medicine Mahidol University Medicine Purpose: To evaluate the efficacy and safety of intralesional injection of bevacizumab on primary pterygium treatment. Methods: In this randomized controlled trial, each primary pterygium patient was randomized to receive either an intralesional injection of bevacizumab 2 mg (1 mg/0.04 mL) or a combination of topical antihistamine (antazoline HCl 0.05%) and vasoconstrictor (tetrahydrozoline HCl 0.04%) as a control. The main outcome measurements were symptoms and signs (including eye irritation, epiphora, redness, amount of discharge, inflammation and elevation of pterygium, and percentage of corneal pterygium area). Results: A total of 74 pterygium eyes in 66 patients were randomized and allocated into a treatment group (N = 34) and a control group (N = 40). In the treatment group, there was a statistically significant reduction of symptoms (including irritation, photophobia, epiphora, redness, discharge, and blurred vision) and signs (inflammation and corneal pterygium area) compared with the baseline, up to at least 6 months. Between the treatment and control groups, no significant differences were found for all visits with respect to the (1) symptoms, (2) signs, and (3) percentage of corneal pterygium. Conclusions: Intralesional bevacizumab may have a therapeutic effect on symptoms and signs of primary pterygium for at least 6 months (ie, the follow-up period), with no serious ocular or systemic adverse effects. Copyright © 2011 by Lippincott Williams & Wilkins. 2018-05-03T08:23:37Z 2018-05-03T08:23:37Z 2011-11-01 Article Cornea. Vol.30, No.11 (2011), 1213-1218 10.1097/ICO.0b013e31821c9b44 15364798 02773740 2-s2.0-80053621316 https://repository.li.mahidol.ac.th/handle/123456789/12245 Mahidol University SCOPUS https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=80053621316&origin=inward |
institution |
Mahidol University |
building |
Mahidol University Library |
continent |
Asia |
country |
Thailand Thailand |
content_provider |
Mahidol University Library |
collection |
Mahidol University Institutional Repository |
topic |
Medicine |
spellingShingle |
Medicine Orapin Enkvetchakul Onsiri Thanathanee Ram Rangsin Kaevalin Lekhanont Olan Suwan-Apichon A randomized controlled trial of intralesional bevacizumab injection on primary pterygium: Preliminary results |
description |
Purpose: To evaluate the efficacy and safety of intralesional injection of bevacizumab on primary pterygium treatment. Methods: In this randomized controlled trial, each primary pterygium patient was randomized to receive either an intralesional injection of bevacizumab 2 mg (1 mg/0.04 mL) or a combination of topical antihistamine (antazoline HCl 0.05%) and vasoconstrictor (tetrahydrozoline HCl 0.04%) as a control. The main outcome measurements were symptoms and signs (including eye irritation, epiphora, redness, amount of discharge, inflammation and elevation of pterygium, and percentage of corneal pterygium area). Results: A total of 74 pterygium eyes in 66 patients were randomized and allocated into a treatment group (N = 34) and a control group (N = 40). In the treatment group, there was a statistically significant reduction of symptoms (including irritation, photophobia, epiphora, redness, discharge, and blurred vision) and signs (inflammation and corneal pterygium area) compared with the baseline, up to at least 6 months. Between the treatment and control groups, no significant differences were found for all visits with respect to the (1) symptoms, (2) signs, and (3) percentage of corneal pterygium. Conclusions: Intralesional bevacizumab may have a therapeutic effect on symptoms and signs of primary pterygium for at least 6 months (ie, the follow-up period), with no serious ocular or systemic adverse effects. Copyright © 2011 by Lippincott Williams & Wilkins. |
author2 |
Khon Kaen University |
author_facet |
Khon Kaen University Orapin Enkvetchakul Onsiri Thanathanee Ram Rangsin Kaevalin Lekhanont Olan Suwan-Apichon |
format |
Article |
author |
Orapin Enkvetchakul Onsiri Thanathanee Ram Rangsin Kaevalin Lekhanont Olan Suwan-Apichon |
author_sort |
Orapin Enkvetchakul |
title |
A randomized controlled trial of intralesional bevacizumab injection on primary pterygium: Preliminary results |
title_short |
A randomized controlled trial of intralesional bevacizumab injection on primary pterygium: Preliminary results |
title_full |
A randomized controlled trial of intralesional bevacizumab injection on primary pterygium: Preliminary results |
title_fullStr |
A randomized controlled trial of intralesional bevacizumab injection on primary pterygium: Preliminary results |
title_full_unstemmed |
A randomized controlled trial of intralesional bevacizumab injection on primary pterygium: Preliminary results |
title_sort |
randomized controlled trial of intralesional bevacizumab injection on primary pterygium: preliminary results |
publishDate |
2018 |
url |
https://repository.li.mahidol.ac.th/handle/123456789/12245 |
_version_ |
1763496294672760832 |